Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC

Loading news article.

Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC | WAPE

Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC

Article summary

Related companies

Comments —